Advertisement

Topics

$SGEN Achieves $30M Milestone Payment for EC Approval of ADCETRIS® in Frontline Hodgkin Lymphoma $TAK https://www.businesswire.com/news/home/20190211005174/en/Seattle-Genetics-Achieves-30-Million-Milestone-Payment …

08:03 EST 11 Feb 2019 | Odi Bruckman

Achieves $30M Milestone Payment for EC Approval of ADCETRIS® in Frontline Hodgkin Lymphoma https://www.businesswire.com/news/home/20190211005174/en/Seattle-Genetics-Achieves-30-Million-Milestone-Payment …

Original Article: $SGEN Achieves $30M Milestone Payment for EC Approval of ADCETRIS® in Frontline Hodgkin Lymphoma $TAK https://www.businesswire.com/news/home/20190211005174/en/Seattle-Genetics-Achieves-30-Million-Milestone-Payment …

NEXT ARTICLE

More From BioPortfolio on "$SGEN Achieves $30M Milestone Payment for EC Approval of ADCETRIS® in Frontline Hodgkin Lymphoma $TAK https://www.businesswire.com/news/home/20190211005174/en/Seattle-Genetics-Achieves-30-Million-Milestone-Payment …"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...